智通财经APP讯，瑞联新材(688550.SH)披露2025年度业绩快报，2025年度实现营业收入16.77亿元，同 比增长14.95%;归属于母公司所有者的净利润3.11亿元，同比增长23.48%。 报告期内，显示材料板块平稳发展，2025年度收入增长主要体现在医药及电子材料板块，其中医药板块 主力产品客户调整库存策略、核心产品进一步放量，推动销售收入增长;电子材料板块随着公司半导体 光刻胶单体材料验证工作的顺利推进，并成功导入部分封装材料产品，带动了相关业务的增长。本年度 公司持续着力提升经营管理效率，深化降本增效，通过节约挖潜、精益流程进一步完善管理体系，强化 研产供销协同，降低生产成本，推动盈利能力提升。 ...

Group 1 - The company announced that its 10th Board of Directors' 18th meeting was held on February 13, 2026, via communication voting [1] - The meeting reviewed proposals including the election of the company's chairman and the heads of certain board committees [1] Group 2 - The company experienced a dramatic shift in net profit, increasing ninefold before suddenly reporting a loss exceeding 200 million [1] - The chairman personally contributed 50 million to cover the financial shortfall, raising questions among shareholders [1] - There are uncertainties regarding the whereabouts of 5 billion in trust financial products, leading to confusion among investors [1]

证券日报网讯 2月13日，瑞丰高材在互动平台回答投资者提问时表示，电池负极材料是公司黑磷产品重 要的下游应用开拓领域。通过将黑磷与石墨等材料按优化比例进行机械球磨复合，可制备高性能磷碳负 极材料。黑磷的理论比容量是石墨的7倍，以磷碳作为负极材料，可显著提升电池的能量密度；同时黑 磷材料特殊的层状结构和高电子电导率，可提高充电速率。公司经过初步试验，黑磷可以作为负极材料 应用到固态电池体系。黑磷若商业化应用于固态电池尚需大量优化及测试试验，目前尚处于早期阶段。 请投资者充分认识目前所处阶段，注意投资风险。公司控股子公司瑞丰玥能的吨级中试装置已安装完成 并进入调试阶段，待调试完成后将尽快投料试生产。具体项目/业务进展情况请以公司公开披露的信息 为准。 （文章来源：证券日报） ...

截至2026年1月20日，公司股东户数为3.32万户，较上期减少2.99%。 业绩经营情况 财务方面，2025年前三季度营业收入39.54亿元，同比增长13.45%，归母净利润8004.33万元，同比增长 2.08%。目前公开资料未显示有重大未来事件公告，市场关注点可能集中于公司日常交易动态和基本面 变化。 以上内容基于公开资料整理，不构成投资建议。 经济观察网德联集团（002666）近期股价和资金流向出现波动，股东户数有所减少，前三季度营收实现 增长。 股票近期走势 2026年2月2日，该股盘中下跌2.11%，报收5.57元/股，成交额3722.38万元，主力资金净流出34.47万 元。 股东人数情况 ...

南财智讯2月13日电，瑞联新材发布2025年度业绩快报，报告期内公司实现营业收入16.77亿元，同比增 长14.95%；归属于上市公司股东的净利润3.11亿元，同比增长23.48%；基本每股收益1.80元，同比增长 24.14%。 ...

经济观察网 根据近7天（2026年2月6日至13日）的公开信息，凯龙股份（002783）（002783）的热点主 要集中在公司治理事件和股价动态。以下是分类总结，重要模块前置。数据均经过交叉验证，确保准确 性。 近期事件 股价表现：近7日股价震荡，区间最高价10.18元（2月11日），最低价9.83元（2月12日）。截至2月13日 最新价9.91元，较2月9日开盘价10.09元累计下跌0.30%，同期振幅3.52%，弱于化学制品板块 （-0.91%）但跑赢上证指数（-0.60%）。 成交情况：2月12日成交额显著放大至1.12亿元，换手率2.47%，随后回落至2月13日的0.84%。融资余额 近5日减少0.05亿元，降幅1.02%，但2月12日融资净买入193万元，显示短期资金分歧。 机构观点 机构预测：根据1家机构最新预测，2025年公司净利润预计同比增长61.99%，2026年预计增长15.42%。 当前市场舆情中性，机构调研频率较低，盈利预期仍以2025年三季报为基础（归母净利润1.35亿元，同 比增长20.64%）。 以上内容基于公开资料整理，不构成投资建议。 2026年2月12日，凯龙股份公告202 ...

Group 1 - The stock price of Shuangle Co., Ltd. has recently increased, but the 2025 performance forecast indicates a net profit decrease of over 50% year-on-year [1][3] - As of February 11, 2026, Shuangle's stock price rose by 2.17% to 35.84 CNY per share, with a trading volume of 75.268 million CNY and a net inflow of main funds amounting to 2.825 million CNY [2] - The company expects a net profit attributable to shareholders for the year 2025 to be between 48 million CNY and 58 million CNY, representing a year-on-year decrease of 51.95% to 60.23% due to intense market competition, fluctuations in downstream demand, and reduced government subsidies [3] Group 2 - Shuangle Co., Ltd. specializes in phthalocyanine and chromium-based pigments, operating within the basic chemical - chemical products sector [4] - The chemical industry is currently undergoing a structural adjustment period, with policy direction focusing on green transformation, and the company's price-to-earnings ratio (TTM) is relatively high [4]

Core Viewpoint - Company is transforming into a comprehensive technology service provider through the acquisition of a 40% stake in Hanxing Energy, while making progress in sustainable aviation fuel catalysts and carbon dioxide capture [1][2][4]. Recent Events - On December 23, 2025, the company announced its wholly-owned subsidiary's plan to acquire 40% of Hanxing Energy for 200 million yuan, aiming to integrate molecular sieve materials and process engineering capabilities [2]. - On February 9, 2026, during an investor survey, the company emphasized that this move is part of a long-term strategic layout to enhance its "materials + processes + equipment" full-chain solution capabilities [2]. Company Structure and Governance - On February 6, 2026, the company held its 17th meeting of the fourth board of directors, reviewing documents related to governance and funding arrangements, including a proposal to provide guarantees for its wholly-owned subsidiary [3]. Institutional Research - On January 23, 2026, the company was surveyed by multiple institutions, revealing advancements in sustainable aviation fuel catalysts and carbon capture utilization and storage (CCUS) [4]. - The company stated that the SAF market has broad prospects, with its specialized molecular sieve catalysts having completed downstream side-line testing, and CCUS being a key new direction under the "dual carbon" goals [4]. Financial Movements - As of February 2, 2026, the company's financing balance was 134 million yuan, accounting for 3.95% of its circulating market value, at a near one-year high; on the same day, net financing sold out was 627,600 yuan, with a stock price drop of 2.40% [5]. - The company's Q3 2025 report showed revenue of 590 million yuan for the first three quarters (up 4.34% year-on-year) and a net profit attributable to shareholders of 72.73 million yuan (up 20.15% year-on-year) [5]. - Recent shareholder changes include a reduction of 892,100 shares announced on January 5, 2026, and three institutions have given buy ratings in the last 90 days [5].

Group 1 - The core viewpoint is that Jiangnan Chemical and Beihua Co., Ltd. do not have a competitive relationship despite both being controlled by China Ordnance Industry Group [2] - Jiangnan Chemical confirmed on the investor interaction platform that their business segments are different from those of Beihua Co., Ltd. [2]

Company and Industry Summary Company Overview - The company focuses on agricultural protection and pharmaceuticals, covering four main sectors: agricultural protection, pharmaceuticals, functional chemicals, and equipment and engineering technology [1][1] - Established nearly 40 years ago, the company has 8 chemical production bases, 3 mechanical equipment production bases, and 3 R&D centers in China, along with one production base each in the UK and Malaysia [1][1] Key Points Agricultural Protection Sector - The agricultural protection CDMO (Contract Development and Manufacturing Organization) business has emerged from a low point and is now in a stable growth phase, serving major global agricultural protection companies [1][1] - Revenue in this sector is expected to slightly decline in 2023-2024 due to downstream inventory destocking [1][1] Pharmaceutical Sector - The company’s pharmaceutical CDMO business has seen a continuous increase in revenue share over the years, primarily serving the top twenty global pharmaceutical companies [2][2] - The pharmaceutical business is extending into the small nucleic acid drug raw material field, with rapid revenue growth anticipated due to increasing downstream customer demand [3][3] New Energy Sector - The company entered the new energy sector in 2021, with LiFSI (Lithium bis(fluorosulfonyl)imide) already commercialized [3][3] - The completion of technical upgrades for lithium hexafluorophosphate will enable the production of 200,000 tons of electrolyte, with 100,000 tons already constructed, contributing to new revenue streams [3][3] Financial Projections - Projected revenues for 2025-2027 are estimated at 6.312 billion, 7.373 billion, and 8.813 billion yuan, respectively, with net profits of 393 million, 513 million, and 617 million yuan [4][4] - Corresponding price-to-earnings ratios (PE) are expected to be 28.0, 21.5, and 17.8 times, respectively, with an initial coverage rating of "Accumulate" [4][4] Additional Insights - The company is replacing some old production capacity with new capacity for patented products, which is expected to enhance gross margins as the supply of off-patent products clears [2][2] - Strengthening relationships with partners is anticipated to lead to rapid growth in demand for patented products [2][2]